Advertisement

Brain-derived neurotrophic factor (BDNF) polymorphisms G196A and C270T are not associated with response to electroconvulsive therapy in major depressive disorder

  • Huuhka KaijaEmail author
  • Anttila Sami
  • Huuhka Martti
  • Leinonen Esa
  • Rontu Riikka
  • Mattila Kari
  • Lehtimäki Terho
ORIGINAL PAPER

Abstract

The aim of the present study was to examine an association of brain-derived neurotrophic factor (BDNF) polymorphisms G196A and C270T and the response to electroconvulsive therapy (ECT) in major depressive disorder (MDD). The study group consisted of 119 patients consecutively admitted for ECT in the Department of Psychiatry, Tampere University Hospital. All patients fulfilled the diagnostic criteria of DSM-IV for MDD. ECT was administered three times a week with a brief pulse constant current device. The Montgomery and Åsberg Depression Rating Scale (MADRS) was used as an outcome measure of depression. Genotyping was performed using fluorescent allele-specific TaqMan probes. No association between either G196A or C270T and the response to ECT was found in the whole population. There were no significant differences in responses between men and women or between psychotic and non-psychotic patients. However, within subgroups such as in psychotic and in late-onset depression CC genotype of C270T may predict good response. BDNF may not be associated with response to ECT in general, but some association in subgroups may exist.

Keywords

BDNF polymorphism major depressive disorder electroconvulsive therapy 

References

  1. 1.
    Duffy A, Grof P, Robertson C, Alda M (2000) The implications of genetics studies of major mood disorders for clinical practice. J Clin Psychiatry 61:630–637PubMedGoogle Scholar
  2. 2.
    American Psychiatric Association (2001) The practice of electroconvulsive therapy: recommendations for treatment, training and privileging: a task force report of the American Psychiatric Association. American Psychiatric Association, Washington, DCGoogle Scholar
  3. 3.
    Maisonpierre PC, Le Beau MM, Espinosa R 3rd, Ip NY, Belluscio L, de la Monte SM, Squinto S, Furth ME, Yancopoulos GD (1991) Human and rat brain-derived neurotrophic factor and neurotrophin-3: gene structures, distributions, and chromosomal localizations. Genomics 10:558–568PubMedCrossRefGoogle Scholar
  4. 4.
    Hashimoto K, Shimizu E, Iyo M (2004) Critical role of brain-derived neurotrophic factor in mood disorders. Brain Res Rev 45:104–114PubMedCrossRefGoogle Scholar
  5. 5.
    Korte M, Carroll P, Wolf E, Brem G, Thoenen H, Bonhoeffer T (1995) Hippocampal long-term potentiation is impaired in mice lacking brain-derived neurotrophic factor. Proc Natl Acad Sci USA 92:8856–8860PubMedCrossRefGoogle Scholar
  6. 6.
    Korte M, Griesbeck O, Gravel C, Carroll P, Staiger V, Thoenen H, Bonhoeffer T (1996) Virus-mediated gene transfer into hippocampal CA1 region restores long-term potentiation in brain-derived neurotrophic factor mutant mice. Proc Natl Acad Sci USA 93:12547–12552PubMedCrossRefGoogle Scholar
  7. 7.
    Altar CA (1999) Neurotrophins and depression. Trends Pharmacol Sci 20:59–61PubMedCrossRefGoogle Scholar
  8. 8.
    Smith MA, Makino S, Kvetnansky R, Post RM (1995) Stress and glucocorticoids affect the expression of brain-derived neurotrophic factor and neurotrophin-3 mRNAs in the hippocampus. J Neurosci 15:1768–1777PubMedGoogle Scholar
  9. 9.
    Angelucci F, Aloe L, Vasquez PJ, Mathe AA (2000) Mapping the differences in the brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) in an animal model of depression. Neuroreport 11:1369–1373PubMedCrossRefGoogle Scholar
  10. 10.
    Okamoto H, Shino Y, Hashimoto K, Kumakiri C, Shimizu E, Shirasawa H, Iyo M (2003) Dynamic changes in AP-1 transcription factor DNA binding activity in rat brain following administration of antidepressant amitriptyline and brain-derived neurotrophic factor. Neuropharmacology 45:251–259PubMedCrossRefGoogle Scholar
  11. 11.
    Siuciak JA, Lewis DR, Wiegand SJ, Lindsay RM (1997) Antidepressant-like effect of brain-derived neurotrophic factor (BDNF). Pharmacol Biochem Behav 56:131–137PubMedCrossRefGoogle Scholar
  12. 12.
    Duman RS (2004) Role of neurotrophic factors in the etiology and treatment of mood disorders. Neuromolecular Med 5:11–25PubMedCrossRefGoogle Scholar
  13. 13.
    Sheline YI (2003) Neuroimaging studies of mood disorder effects on the brain. Biol Psychiatry 54:338–352PubMedCrossRefGoogle Scholar
  14. 14.
    Bielau H, Trübner K, Krell D, Agelink MW, Bernstein H-G, Stauch R, Mawrin C, Danos P, Gerhard L, Bogerts B, Baumann B (2005) Volume deficits of subcortical nuclei in mood disorders A postmortem study. Eur Arch Psychiatry Clin Neurosci 255:401–412PubMedCrossRefGoogle Scholar
  15. 15.
    Duman RS, Vaidya VA (1998) Molecular and cellular actions of chronic electroconvulsive seizures. J ECT 14:181–193PubMedGoogle Scholar
  16. 16.
    Malberg JE, Eisch AJ, Nestler EJ, Duman RS (2000) Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci 20:9104–9110PubMedGoogle Scholar
  17. 17.
    Vaidya VA, Siuciak JA, Du F, Duman RS (1999) Hippocampal mossy fiber sprouting induced by chronic electroconvulsive seizures. Neuroscience 89:157–166PubMedCrossRefGoogle Scholar
  18. 18.
    Zetterstrom TS, Pei Q, Grahame-Smith DG (1998) Repeated electroconvulsive shock extends the duration of enhanced gene expression for BDNF in rat brain compared with a single administration. Brain Res Mol Brain Res 57:106–110PubMedCrossRefGoogle Scholar
  19. 19.
    Altar CA, Laeng P, Jurata LW, Brockman JA, Lemire A, Bullard J, Bukhman YV, Young TA, Charles V, Palfreyman MG (2004) Electroconvulsive seizures regulate gene expression of distinct neurotrophic signaling pathways. J Neurosci 24:2667–2677PubMedCrossRefGoogle Scholar
  20. 20.
    Chen B, Dowlatshahi D, MacQueen GM, Wang JF, Young LT (2001) Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication. Biol Psychiatry 15(50):260–265CrossRefGoogle Scholar
  21. 21.
    Gonul AS, Akdeniz F, Taneli F, Donat O, Eker C, Vahip S (2005) Effect of treatment on serum brain-derived neurotrophic factor levels in depressed patients. Arch Psychiatry Clin Neurosci 255:381–386CrossRefGoogle Scholar
  22. 22.
    Egan MF, Kojima M, Callicott JH, Goldberg TE, Kolachana BS, Bertolino A, Zaitsev E, Gold B, Goldman D, Dean M, Lu B, Weinberger DR (2003) The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 112:257–269PubMedCrossRefGoogle Scholar
  23. 23.
    Kunugi H, Iijima Y, Tatsumi M, Yoshida M, Hashimoto R, Kato T, Sakamoto K, Fukunaga T, Inada T, Suzuki T, Iwata N, Ozaki N, Yamada K, Yoshikawa T (2004) No association between the Val66Met polymorphism of the brain-derived neurotrophic factor gene and bipolar disorder in a Japanese population: a multicenter study. J Biol Psychiatry 56:376–378CrossRefGoogle Scholar
  24. 24.
    Nakata K, Ujike H, Sakai A, Uchida N, Nomura A, Imamura T, Katsu T, Tanaka Y, Hamamura T, Kuroda S (2003) Association study of the brain-derived neurotrophic factor (BDNF) gene with bipolar disorder. Neurosci Lett 337:17–20PubMedCrossRefGoogle Scholar
  25. 25.
    Neves-Pereira M, Mundo E, Muglia P, King N, Macciardi F, Kennedy JL (2002) The brain-derived neurotrophic factor gene confers susceptibility to bipolar disorders: evidence from a family-based association study. Am J Hum Genet 71:651–655PubMedCrossRefGoogle Scholar
  26. 26.
    Neves-Pereira M, Cheung JK, Pasdar A, Zhang F, Breen G, Yates P, Sinclair M, Crombie C, Walker N, St Clair DM (2005) BDNF gene is a risk factor for schizophrenia in a Scottish population. Mol Psychiatry 10:208–212PubMedCrossRefGoogle Scholar
  27. 27.
    Sklar P, Gabriel SB, McInnis MG, Bennett P, Lim Y-M, Tsan G, Schaffner S, Kirov G, Jones I, Owen M, Craddock N, De Paulo JR, Lander ES (2002) Family-based association study of 76 candidate genes in bipolar disorder: BDNF is a potential risk locus. Mol Psychiatry 7:579–593PubMedCrossRefGoogle Scholar
  28. 28.
    Hong C-J, Huo S-J, Yen F-C, Tung C-L, Pan G-M, Tsai S-J (2003) Association study of a brain-derived neurotrophic-factor genetic polymorphism and mood disorders, age of onset and suicidal behavior. Neuropsychobiology 448:186–189CrossRefGoogle Scholar
  29. 29.
    Tsai S-J, Cheng C-Y, Yu YW-Y, Chen T-J, Hong C-J (2003) Association study of a brain derived neurotrophic-factor genetic polymorphism and major depressive disorders, symptomatology and antidepressant response. Am J Med Gen 123B:19–22CrossRefGoogle Scholar
  30. 30.
    Lam P, Cheng CY, Hong CJ, Tsai SJ (2004) Association study of a brain-derived neurotrophic factor (Val66Met) genetic polymorphism and panic disorder. Neuropsychobiology 49:178–181PubMedCrossRefGoogle Scholar
  31. 31.
    American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders, (4th edn). American Psychiatric Press, Washington, DCGoogle Scholar
  32. 32.
    Swartz CM, Abrams R (1996) ECT Instruction manual, (6th edn). Somatic Inc., Lake Bluff, IllinoisGoogle Scholar
  33. 33.
    Montgomery SA, Åsberg M (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382–389PubMedGoogle Scholar
  34. 34.
    Folstein MF, Folstein SE, McHugh PR (1975) A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 14:189–198CrossRefGoogle Scholar
  35. 35.
    Livak KJ (1999) Allelic discrimination using fluorogenic probes and the 5′ nuclease assay. Genet Anal 14:143–149PubMedGoogle Scholar
  36. 36.
    Kearns NP, Cruickshank CA, McGuigan KJ, Riley SA, Shaw SP, Snaith RP (1982) A comparison of depression rating scales. Br J Psychiatry 141:45–49PubMedCrossRefGoogle Scholar
  37. 37.
    Fisman M, Rabheru K, Hegele RA, Sharma V, Fisman D, Doering M, Appell J (2001) Apolipoprotein E polymorphism and response to electroconvulsive therapy. J ECT 17:11–14PubMedCrossRefGoogle Scholar
  38. 38.
    Krishnan KR, Tupler LA, Ritchie JC Jr, McDonald WM, Knight DL, Nemeroff CB, Carroll BJ (1996) Apolipoprotein E-epsilon 4 frequency in geriatric depression. Biol Psychiatry 4:69–71CrossRefGoogle Scholar
  39. 39.
    Zupenko GS, Henderson R, Stiffler JS, et al. (1996) Association of the APOE, 4 allele with clinical subtypes of late life depression. Biol Psychiatry 40:1008–1016CrossRefGoogle Scholar
  40. 40.
    Kanemoto K, Kawasaki J, Tarao Y, Kumaki T, Oshima T, Kaji R, Nishimura M (2003) Association of partial epilepsy with brain-derived neurotrophic factor (BDNF) gene polymorphisms. Epilepsy Res 53:255–258PubMedCrossRefGoogle Scholar
  41. 41.
    Duman RS, Heninger GR, Nestler EJ (1997) A molecular and cellular theory of depression. Arch Gen Psychiatry 54:597–606PubMedGoogle Scholar
  42. 42.
    Schumacher J, Jamra RA, Becker T, Ohlraun S, Klopp N, Binder EB, Schulze TG, Deschner M, Schmäl C, Höfels S, Zobel A, Illig T, Propping P, Holsboer F, Rietscel M, Nöthen MM, Cichon S (2005) Evidence for a relationship between genetic variants at the brain-derived neurotrophic factor (BDNF) locus and major depression. Biol Psychiatry 58:307–314PubMedCrossRefGoogle Scholar
  43. 43.
    Huuhka M, Anttila S, Leinonen E, Huuhka K, Rontu R, Mattila KM, Huhtala H, Lehtimaki T (2005) The apolipoprotein E polymorphism is not associated with response to electroconvulsive therapy in major depressive disorder. J ECT 21:7–11PubMedCrossRefGoogle Scholar

Copyright information

© Steinkopff Verlag Darmstadt 2006

Authors and Affiliations

  • Huuhka Kaija
    • 1
    • 2
    Email author
  • Anttila Sami
    • 1
    • 3
  • Huuhka Martti
    • 1
    • 2
  • Leinonen Esa
    • 1
    • 2
  • Rontu Riikka
    • 1
    • 3
  • Mattila Kari
    • 1
    • 3
  • Lehtimäki Terho
    • 1
    • 3
  1. 1.Medical SchoolUniversity of TampereTampereFinland
  2. 2.Department of PsychiatryTampere University HospitalPitkäniemiFinland
  3. 3.Laboratory of Atherosclerosis Genetics, Department of Clinical Chemistry, Centre of Laboratory MedicineTampere University HospitalTampereFinland

Personalised recommendations